Skip to main content

Gilead Sciences Inc(GILD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low132.22
Day High136.34
Open:136.18
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Zacks Investment Research
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Tipranks
Wall Street Analysts Are Neutral on Top Healthcare Picks
Tipranks
Morgan Stanley Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Tipranks
Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
Tipranks
Scotiabank Reaffirms Their Buy Rating on Gilead Sciences (GILD)
StockStory
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
MHK
StockStory
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
GILD
Tipranks
Gilead price target raised to $175 from $171 at Morgan Stanley
Tipranks
Morgan Stanley Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Tipranks
Gilead price target raised to $155 from $152 at Truist
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Nuvalent (NUVL) and Innoviva (INVA)
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Viatris (VTRS) and Insmed (INSM)
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Soleno Therapeutics (SLNO)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Gilead Sciences (GILD) Gets a Buy from Cantor Fitzgerald
Quiver Quantitative, Inc.
Gilead to Acquire Tubulis for Up to $5 Billion to Expand Cancer Drug Pipeline
Tipranks
Gilead Sciences (GILD) Receives a Buy from Bernstein
Zacks Investment Research
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Tipranks
Analysts’ Top Healthcare Picks: Centene (CNC), Eli Lilly & Co (LLY)
Tipranks
Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
Zacks Investment Research
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD)
Tipranks
Gilead Ends Obeldesivir Filovirus Prophylaxis Trial: What It Means for GILD Investors
Newswire.ca
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atara Biotherapeutics (ATRA), DocGo (DCGO) and Gilead Sciences (GILD)
StockStory
3 Reasons to Avoid GILD and 1 Stock to Buy Instead
GILD
Motley Fool
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Zacks Investment Research
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD)
Tipranks
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)
Motley Fool
2 Recession-Resistant Dividend Stocks to Buy Now
MarketBeat
3 Blue-Chip Stocks Built for a Rotating Market
MarketBeat.com

Profile

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.